Spectral Medical Inc. provided an update on the Company's Tigris trial, a Phase 3 follow-on study evaluating the use of Polymyxin B Hemoperfusion ("PMX") in a randomized controlled trial of adults treated for endotoxemia and septic shock. Enrollment: Robust enrollment activity continuing throughout the first half of 2024: 116 patients enrolled at end of June 2024; Record monthly enrollment with nine patients enrolled in June; Thirty-five patients enrolled in 2024 so far - represents the most robust enrollment rates since the start of the Tigris study; With 34 patients to full enrollment, the Company is entering the final push to fully enroll and finish the Tigris trial Trial Sites: Currently 23 clinical sites; Recently onboarded the Thomas Jefferson University; an experienced, high-quality site from the EUPHRATES trial; Spectral clinical team focused on trial site management activities to ensure that Tigris sites have the support and resources to enroll patients as efficiently as possible.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.51 CAD | -1.92% |
|
+4.08% | +20.00% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+20.00% | 107M | |
+61.53% | 856B | |
+38.95% | 631B | |
-3.66% | 359B | |
+15.06% | 325B | |
+9.18% | 297B | |
+5.89% | 234B | |
+16.53% | 226B | |
+15.67% | 177B | |
+2.47% | 165B |
- Stock Market
- Equities
- EDT Stock
- News Spectral Medical Inc.
- Spectral Medical Inc. Provides June Tigris Trial Update